

USE OF METRONIDAZOLE FOR THE PREPARATION OF A  
PHARMACEUTICAL COMPOSITION FOR TREATING PATHOLOGIES  
ASSOCIATED WITH THE INTERLEUKIN 8 TYPE B RECEPTOR  
AND/OR THE PACAP TYPE 1 RECEPTOR

5

The present invention relates to the field of treating  
pathologies associated with the interleukin 8 type B  
receptor and/or the PACAP type 1 receptor. The  
invention is directed towards providing novel  
10 pharmaceutical compositions, more particularly  
dermatological compositions, which comprise  
metronidazole as active agent.

Rosacea is a common, chronic and progressive  
15 inflammatory dermatitis associated with vascular  
instability. It mainly affects the central part of the  
face and is characterized by redness of the face or hot  
flushes, facial erythema, papules, pustules and  
telangiectasia. In serious cases, especially in men,  
20 the soft tissue of the nose may swell and produce a  
bulbous swelling known as rhinophyma.

Rosacea generally occurs between the ages of 25 and 70,  
and is much more common in people of fair complexion.  
25 It more particularly affects women, although this  
affection is generally more severe in men. Rosacea is  
chronic and lasts for years with periods of  
exacerbation and of remission.

30 Rosacea was originally called "acne rosacea" because  
its papules (points of slight raising of the skin) and  
its inflammatory pustules (pus scabs) greatly resemble  
those of common acne. In contrast with common acne,  
whose aetiology is based on abnormal keratinization, an  
35 increase in sebum production and also bacterial  
inflammation, the inflammation of rosacea is vascular  
in nature and is poorly understood. The result of this  
facial vascular anomaly is a permanent oedema of the  
dermis, which may be accompanied by an increased

colonization with *Demodex folliculorum*, a mite usually found in the follicles of the face.

According to various studies, *Demodex folliculorum* is  
5 thought to have an aetiological role in rosacea (Erbagi  
et al. 1998, Int. J. Dermatol., vol. 37, pages 421-425;  
Purcell et al. 1986, J. Am. Acad. Dermatol., vol. 15,  
pages 1159-1162; Sibenge et al. 1992, J. Am. Acad.  
Dermatol., vol. 26, pages 590-593). It appears that  
10 *Demodex folliculorum* causes or aggravates inflammatory  
reactions, reflected by papules and pustules, by  
blocking the pilosebaceous follicles of the face (Roihu  
et al. 1998, J. Cutan. Pathol., vol. 25, pages 550-  
552). This parasite is moreover thought to trigger a  
15 humoral immune response (Nunzi et al. 1980, Br. J.  
Dermatol., vol. 103, pages 543-551; Manna et al. 1982,  
Br. J. Dermatol., vol. 107, pages 203-208).

The pathogenesis of rosacea is poorly understood. Many  
20 factors may be involved without necessarily inducing  
this complaint. They are, for example, psychological  
factors, gastrointestinal disorders, environmental  
factors (exposure to sunlight, temperature, humidity),  
emotional factors (stress), dietary factors (alcohol,  
25 spices), hormonal factors or vascular factors, or even  
infection with *Helicobacter pylori*.

Rosacea develops in four stages, but passage through  
all the stages is not obligatory:

30 - stage 1 of vascular relaxation (at about 20  
years old). The patients have sudden bursts of  
paroxystic redness of the face and neck, with a hot  
sensation, but with no systemic signs. After the  
attacks, the skin of the face returns to normal. These  
35 "flushes" are triggered by changes in temperature  
(occasionally leading to thermophobia), and the intake  
of hot drinks or alcohol;

- stage 2 of erythemato-telangiectasia (at about  
30 years old). The cheekbone areas are diffusely red.

Dilated capillaries constituting standard acne rosacea are observed therein. In contrast with stage 1, the redness is permanent. Besides the cheeks, the chin and the middle of the forehead may be affected;

5           - stage 3 of papulo-pustules (at about 40 years old). Papules and pustules a few millimetres in diameter develop on a background of erythema, without associated comedones. This dermatitis may be very extensive, occasionally up to the bald part of the  
10 scalp in men, but is absent from the area around the mouth and the eyes. The patients complain of sensitive skin, with subjective intolerance to the majority of topical products and greasy cosmetics;

          - stage 4 of rhinophyma (at about 50 years old or  
15 later). This late phase mainly affects men, in contrast with the other stages. The nose is increased in volume and diffusely red, and the follicular orifices are dilated. The skin gradually thickens.

20 The minor forms of rosacea may be treated with active agents such as anti-seborrhoeic agents and anti-infectious agents, for example benzoyl peroxide and retinoic acid. As regards the most diffuse forms of the complaint, they respond well to general antibiotic  
25 therapy with cyclines. However, these treatments have unpleasant side effects for the patient, such as irritation or intolerance phenomena.

Furthermore, on account of the multi-factor aspect of  
30 rosacea, there are a huge number of treatments for this condition, but the search continues for an effective treatment that is without risk for the patient.

The interleukin 8 receptors are seven-domain  
35 transmembrane receptors and are coupled to G proteins. Two interleukin 8 receptors have been identified, named IL-8RA or CXCR1 and IL-8RB or CXCR2.

PACAP,       "pituitary       adenylate       cyclase-activating

peptide", has 68% identity with vasoactive intestinal peptide (VIP), one of the members of the secretin/glucagon/GHRH family. PACAP deploys pleiotropic effects throughout the body during  
5 development, but also in adults. It participates in essential functions such as growth, endocrine and digestive activity, cardiovascular and respiratory control, immune responses and circadian rhythm. It binds to and activates a multitude of receptor  
10 subtypes, some of which (type II) have the particular feature of also binding VIP with the same high affinity. These receptors are widely distributed in the brain and the peripheral tissues. Among the PACAP receptors, the type 1 receptor, PAC-1 (or PVR1), is  
15 known.

PACAP and IL-8 are both involved in inflammation. Specifically, PACAP reduces the release of pro-inflammatory cytokines and inhibits neutrophil  
20 activation.

Metronidazole, or (2-methyl-5-nitroimidazolyl)-2-ethanol, is known in the prior art for its anti-bacterial, anti-parasitic and anti-protozoan  
25 properties. It exerts selective toxicity on anaerobic microorganisms and also on hypoxic cells. In the latter, metronidazole is reduced to derivatives capable of impairing the DNA structure of these cells.

30 The Applicant's studies have demonstrated the involvement of the interleukin 8 type B receptor (L-8RB) and the PACAP type 1 receptor (PAC-1) in certain pathologies and especially in rosacea.

35 As indicated previously, the invention is directed towards offering a novel method for treating pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor. This treatment method consists in

administering to a subject an effective amount of metronidazole, in which the metronidazole is capable of influencing the binding of a ligand to at least one receptor chosen from the group comprising the IL-8RB  
5 receptor and the PAC-1 receptor. Consequently, the invention relates more particularly to the use of metronidazole for the preparation of a pharmaceutical composition for treating pathologies involving at least one receptor chosen from the group comprising the  
10 IL-8RB receptor and the PAC-1 receptor.

More particularly, the invention relates to the use of metronidazole for the preparation of a pharmaceutical composition for treating pathologies involving at least  
15 one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor and in which metronidazole is capable of modulating the interaction of a ligand with at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1  
20 receptor.

The invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition as defined above and in which the metronidazole modulates  
25 the binding of at least one natural ligand to its receptor, the said receptor being chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor.

More particularly, the invention relates to the use of  
30 metronidazole for the preparation of a pharmaceutical composition as defined above, for treating a pathology involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor.

35 The invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition as defined above, for treating a pathology involving two receptors chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor, the said pathology

being rosacea.

More particularly, the pharmaceutical composition that is the subject of the present invention is a dermatological composition for topical application to the skin.

The term "treatment of pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor" means, according to the present invention, the treatment and/or prevention of such a pathology. In particular, these pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor are rosacea, psoriasis, acute and chronic inflammation, autoimmune diseases and septic shock. It will more particularly be rosacea.

According to the present invention, the term "treatment of rosacea" means the treatment and/or prevention of rosacea, at one or more of the stages described above.

According to a first embodiment of the invention, the composition is intended for treating the first stage of rosacea.

According to a second embodiment of the invention, the composition is intended for treating the second stage of rosacea.

According to a third embodiment of the invention, the composition is intended for treating the third stage of rosacea.

According to a fourth embodiment of the invention, the composition is intended for treating the fourth stage of rosacea.

According to one preferential embodiment, the



composition contains from 0.0001% to 20% of metronidazole, preferably from 0.1% to 2% of metronidazole and more preferentially from about 0.75% to 1% of metronidazole expressed by weight relative to  
5 the total weight of the composition.

Needless to say, the present invention concerns, besides the use of metronidazole, the use of derivatives thereof. The term "derivatives" means  
10 compounds that differ from metronidazole by substitution, addition or removal of one or more chemical groups and that have substantially the same activity.

15 Advantageously, the compositions of the invention comprise, besides metronidazole, at least one other therapeutic agent capable of increasing the efficacy of the treatment. Non-limiting examples of such agents that may be mentioned include antibiotics,  
20 antibacterial agents, antiviral agents, antiparasitic agents, antifungal agents, anaesthetics, analgesics, antiallergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, keratolytic agents, anti-seborrhoeic agents, antihistamines,  
25 sulfides, immunosuppressant products and anti-proliferative products.

The compositions of the invention may also comprise any additive usually used in the pharmaceutical or  
30 dermatological field that is compatible with metronidazole. Mention may be made especially of sequestrants, antioxidants, sunscreens, preserving agents, for example DL- $\alpha$ -tocopherol, fillers, electrolytes, humectants, dyes, common mineral or  
35 organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, skin calmativ and protective agents such as allantoin, pro-penetrating agents and

gelling agents.

Needless to say, a person skilled in the art will take care to select this or these optional additional  
5 compound(s), and/or the amount thereof, such that the advantageous properties of the composition according to the invention are not, or are not substantially, adversely affected.

10 These additives may be present in the composition in a proportion of from 0 to 20% by weight relative to the total weight of the composition.

Examples of sequestrants that may be mentioned include  
15 ethylenediaminetetraacetic acid (EDTA), and also derivatives or salts thereof, dihydroxyethylglycine, citric acid and tartaric acid, or mixtures thereof.

Examples of preserving agents that may be mentioned  
20 include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea and parabens, or mixtures thereof.

Examples of humectants that may be mentioned include  
25 glycerol and sorbitol.

The compositions of the invention may contain one or more pro-penetrating agents in preferential concentrations ranging from 0 to 20% and more  
30 preferentially ranging from 0.6% to 3% by weight relative to the total weight of the composition. Among the pro-penetrating agents that are preferentially used, without this list being limiting, are compounds such as propylene glycol, dipropylene glycol, propylene  
35 glycol dipelargonate, lauroglycol and ethoxydiglycol.

Advantageously, the compositions according to the invention may also contain one or more wetting liquid surfactants in preferential concentrations ranging from



0 to 10% and more preferentially ranging from 0.1% to 2%.

5 The compositions of the present invention may be in any galenical form normally used for topical application, especially in the form of aqueous, aqueous-alcoholic or oily solutions, dispersions of the lotion type, aqueous, anhydrous or lipophilic gels, emulsions of liquid or semi-liquid consistency of the milk type,  
10 obtained by dispersing a fatty phase in an aqueous phase (O/W) or, conversely, (W/O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream, gel or ointment type, or alternatively microemulsions, microcapsules, microparticles or  
15 vesicular dispersions of ionic and/or nonionic type.

Preferably, the creams may be formulated from a mixture of mineral oil or from a mixture of beeswax and of water, which emulsifies instantaneously, to which is  
20 added metronidazole, dissolved in a small amount of oil such as almond oil.

The ointments may be formulated by mixing a solution of metronidazole in an oil such as almond oil in warmed  
25 paraffin, followed by leaving the mixture to cool.

As examples of compositions according to the invention, mention may be made of those comprising an active phase containing (expressed as weight percentages):

30 - 0 to 90%, preferentially 5% to 25% and especially 10% to 20% of water;

- 0 to 10%, preferentially 0 to 2% and especially 0 to 0.5% of wetting liquid surfactant;

- 0 to 20%, preferentially 0 to 10% and especially  
35 2% to 5% of pro-penetrating agent;

- 0.0001% to 20% and preferentially 0.1% to 2% of metronidazole;

and an aqueous phase comprising a pH-independent gelling agent, and water.

The aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, a floral water such as cornflower water or a  
5 natural spring or mineral water chosen, for example, from eau de Vittel, the waters of the Vichy basin, eau d'Uriage, eau de la Roche Posay, eau de la Bourboule, eau d'Enghien-les-Bains, eau de Saint Gervais-les-Bains, eau de Nérès-les-Bains, eau d'Allevard-les-  
10 Bains, eau de Digne, eau de Maizières, eau de Neyrac-les-Bains, eau de Lons-le-Saunier, les Eaux Bonnes, eau de Rochefort, eau de Saint Christau, eau des Fumades, eau de Tercis-les-Bains, eau d'Avène and eau d'Aix-les-Bains.

15

The said aqueous phase may be present in a content of between 10% and 90% by weight and preferably between 20% and 80% by weight relative to the total weight of the composition.

20

Non-limiting examples that may be mentioned include gelling agents of the polyacrylamide family such as the sodium acryloyldimethyltaurate copolymer/isoheptadecane/polysorbate-80 mixture sold under the name  
25 Simulgel 600 by the company SEPPIC, the polyacrylamide/C13-14 isoparaffin/laureth-7 mixture, for instance the product sold under the name Sepigel 305 by the company SEPPIC, the family of acrylic polymers coupled to hydrophobic chains, such as the  
30 PEG-150/decyl/SMDI copolymer sold under the name Aculyn 44 (polycondensate comprising at least, as components, a polyethylene glycol containing 150 or 180 mol of ethylene oxide, decyl alcohol and methylenebis(4-cyclohexyl isocyanate) (SMDI), at 35% by weight in a  
35 mixture of propylene glycol (39%) and water (26%)), and the family of modified starches such as the modified potato starch sold under the name Structure Solanace, or mixtures thereof.

The preferred gelling agents are derived from the polyacrylamide family, such as Simulgel 600 or Sepigel 305 or mixtures thereof.

- 5 The gelling agent as described above may be used in preferential concentrations ranging from 0.1% to 15% and more preferentially ranging from 0.5% to 5%.

10 The gels may preferably be prepared by dispersing or dissolving metronidazole in a suitable ratio in a gel of carbomer, poloxamer or cellulose-based type.

Other advantages and characteristics of the invention will emerge from the examples below concerning the  
15 activity of metronidazole.

#### Example 1 - Activity of metronidazole

##### 1) Protocol:

20 The test of binding to the PAC-1 receptor was performed according to the protocol described by Cauvin et al., 1991, Regul Peptides, Vol. 36, pages 161-173.

The test of binding to the IL-8RB receptor was performed according to the protocol described by White  
25 et al., 1998, J Biol Chem, Vol. 273, pages 10095-10098.

##### 2) Experimental conditions:

The binding of metronidazole to each receptor was determined by competitive experiments. The receptor,  
30 human recombinant protein, was incubated for times indicated in Table 1 below, with a single concentration of labelled specific ligand, in the presence of metronidazole at 10  $\mu$ M. The bound radioactivity was measured by scintillation counting.

Table 1

Receptor	Radiolabelled specific ligand	Non-specific ligand	Incubation conditions
IL-8RB	[ <sup>125</sup> I] IL-8 (0.2 nM)	IL-8 (0.3 μM)	60 min/22°C
PAC-1	[ <sup>125</sup> I] PACAP <sub>1-27</sub> (0.2 nM)	PACAP <sub>1-27</sub> (0.1 μM)	30 min/37°C

3) Analysis and expression of the results:

- 5 The specific binding of the ligand to the receptor is defined as the difference between the total binding and the non-specific binding, determined in the presence of an excess of unlabelled ligand.
- 10 The results are expressed as a percentage of control specific binding and as a percentage of inhibition of the control specific binding obtained in the presence of metronidazole (Table 2).

15

Table 2

Receptor	Metronidazole (μM)	% of control specific binding (± SD)
IL-8RB	10	120.8 ± 0.7
PAC-1	10	133.2 ± 13.2

Metronidazole thus induces the binding of the ligand to its IL-8RB receptor and the PAC-1 receptor.